Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

2.

Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.

Giono LE, Resnick-Silverman L, Carvajal LA, St Clair S, Manfredi JJ.

Oncogene. 2017 Aug 14. doi: 10.1038/onc.2017.254. [Epub ahead of print]

PMID:
28806397
3.

Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.

Worrall EG, Wawrzynow B, Worrall L, Walkinshaw M, Ball KL, Hupp TR.

J Chem Biol. 2009 Aug;2(3):113-29. doi: 10.1007/s12154-009-0019-5. Epub 2009 May 16.

4.

Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.

Nihira NT, Ogura K, Shimizu K, North BJ, Zhang J, Gao D, Inuzuka H, Wei W.

Sci Signal. 2017 Feb 14;10(466). pii: eaai8026. doi: 10.1126/scisignal.aai8026.

5.

Mechanisms of p53 degradation.

Chao CC.

Clin Chim Acta. 2015 Jan 1;438:139-47. doi: 10.1016/j.cca.2014.08.015. Epub 2014 Aug 27. Review.

PMID:
25172038
6.

The Regulation of Multiple p53 Stress Responses is Mediated through MDM2.

Hu W, Feng Z, Levine AJ.

Genes Cancer. 2012 Mar;3(3-4):199-208. doi: 10.1177/1947601912454734.

7.

PIG3 Regulates p53 Stability by Suppressing Its MDM2-Mediated Ubiquitination.

Jin M, Park SJ, Kim SW, Kim HR, Hyun JW, Lee JH.

Biomol Ther (Seoul). 2017 Jul 1;25(4):396-403. doi: 10.4062/biomolther.2017.086.

8.

It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Love IM, Grossman SR.

Genes Cancer. 2012 Mar;3(3-4):249-63. doi: 10.1177/1947601912455198.

9.

Mdm2 and tumorigenesis: evolving theories and unsolved mysteries.

Senturk E, Manfredi JJ.

Genes Cancer. 2012 Mar;3(3-4):192-8. doi: 10.1177/1947601912457368.

10.

Regulation of the MDM2-p53 pathway by the nucleolar protein CSIG in response to nucleolar stress.

Xie N, Ma L, Zhu F, Zhao W, Tian F, Yuan F, Fu J, Huang D, Lv C, Tong T.

Sci Rep. 2016 Nov 4;6:36171. doi: 10.1038/srep36171.

11.

Ubiquitin-specific peptidase 48 regulates Mdm2 protein levels independent of its deubiquitinase activity.

Cetkovská K, Šustová H, Uldrijan S.

Sci Rep. 2017 Feb 24;7:43180. doi: 10.1038/srep43180.

12.

Regulation of NUB1 Activity through Non-Proteolytic Mdm2-Mediated Ubiquitination.

Bonacci T, Audebert S, Camoin L, Baudelet E, Iovanna JL, Soubeyran P.

PLoS One. 2017 Jan 18;12(1):e0169988. doi: 10.1371/journal.pone.0169988. eCollection 2017.

13.

Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development.

Laos M, Sulg M, Herranen A, Anttonen T, Pirvola U.

Sci Rep. 2017 Feb 9;7:42216. doi: 10.1038/srep42216.

14.

NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway.

Jana A, Krett NL, Guzman G, Khalid A, Ozden O, Staudacher JJ, Bauer J, Baik SH, Carroll T, Yazici C, Jung B.

Oncotarget. 2017 Jun 6;8(23):37377-37393. doi: 10.18632/oncotarget.16343.

15.

Chromatin-bound MDM2, a new player in metabolism.

Riscal R, Le Cam L, Linares LK.

Mol Cell Oncol. 2016 Jul 15;3(5):e1210560. eCollection 2016.

16.

Mdm2's dilemma: to degrade or to translate p53?

Hamard PJ, Manfredi JJ.

Cancer Cell. 2012 Jan 17;21(1):3-5. doi: 10.1016/j.ccr.2011.12.018.

17.

Erratum to: Hyperglycemia promotes p53-Mdm2 interaction but reduces p53 ubiquitination in RINm5F cells.

Barzalobre-Gerónimo R, Flores-López LA, Baiza-Gutman LA, Cruz M, García-Macedo R, Ávalos-Rodríguez A, Contreras-Ramos A, Díaz-Flores M, Ortega-Camarillo C.

Mol Cell Biochem. 2015 Aug;406(1-2):301. doi: 10.1007/s11010-015-2461-8. No abstract available.

PMID:
26026618
18.

Detection of P53 and Mdm2 in vitiligo.

Wiwanitkit V.

Indian Dermatol Online J. 2013 Jan;4(1):61-2. doi: 10.4103/2229-5178.105492. No abstract available.

19.

Correction: Chemical ubiquitination for decrypting a cellular code.

Stanley M, Virdee S.

Biochem J. 2016 Jul 15;473(14):2249. doi: 10.1042/BJ04732249. No abstract available.

PMID:
27407172

Supplemental Content

Support Center